Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIXAR: Ixazomib + Lenalidomide + Rituximab in Indolent B-Cell Lymphoma
NCT02898259Phase 2Terminated
- Start
- Feb 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in indolent B-cell lymphoma. Started Feb 2017; status: terminated.
02
Drugs
ixazomib
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT02898259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898259.